Encephalitis Treatment Global Market Report 2024

The global encephalitis treatment market has grown strongly in recent years. It will grow from $19.84 billion in 2023 to $21.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high incidence of encephalitis, prevalence of viral or bacterial infection, growing government initiatives, rising demand for preventive encephalitis vaccines.

The global encephalitis treatment market is expected to see strong growth in the next few years. It will grow to $26.17 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising healthcare expenditure, increase in the popularity of physical therapy, growing geriatric population, increasing awareness of encephalitis treatment. Major trends in the forecast period include advanced diagnostic tools, ai and ml in encephalitis diagnosis and treatment, development of personalized medicines, demand for preventive encephalitis vaccines, supportive cares.

The growth of the encephalitis treatment market is expected to be driven by increased investments in healthcare infrastructure. Healthcare infrastructure encompasses facilities, resources, and services that support the delivery of medical care to individuals and communities, including hospitals, clinics, and medical laboratories equipped with advanced technology and staffed by trained healthcare professionals. Effective healthcare infrastructure plays a pivotal role in encephalitis treatment by providing access to specialized medical facilities, diagnostic tools, and supportive care. For example, in May 2023, the American Health Care Association reported that the number of hospitals in the US increased from 6,129 in 2021 to 6,093 in 2022. Additionally, healthcare spending in the UK surged by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021, according to a report by the Office for National Statistics. Therefore, the upward trend in healthcare infrastructure investment is propelling the growth of the encephalitis treatment market.

Anticipated growth in the encephalitis treatment market is attributed to the increasing incidence of neuroinvasive diseases. Neuroinvasive diseases refer to conditions where pathogens like viruses or bacteria enter the nervous system, leading to inflammation or damage to nervous tissues. The growing prevalence of neuroinvasive diseases creates a demand for encephalitis treatments, spurring investments by pharmaceutical companies and researchers in the development of new therapies and medications to address the expanding needs of patients. For example, in June 2023, the Centers for Disease Control and Prevention (CDC) reported 8 cases of neuroinvasive La Crosse virus human disease in September 2022, compared to 6 cases in July 2022. Ohio had the highest total cases reported, with 13 cases, surpassing all other regions in the USA. This underscores the driving force of an increasing number of neuroinvasive disease cases on the encephalitis treatment market's growth.

The substantial expenses linked to encephalitis treatment could have an adverse impact on the encephalitis treatment market's growth. The cost of medications utilized in treating the disease contributes to the high treatment expenses. For example, as of November 2022, the National Library of Medicine, a US-based medical library, estimated the treatment cost for toxoplasmosis encephalitis (TE) to be $50,310 for 66 admissions, with a total drug expenditure of $1,026,006 for 61 admissions. Hence, the high treatment costs associated with encephalitis impede the encephalitis treatment market's growth.

Prominent companies operating in the encephalitis treatment market are actively engaged in developing innovative products and solutions to gain a competitive edge in the market. For instance, in August 2021, Pfizer Inc. received approval from the United States Food and Drug Administration for TICOVAC, a vaccine designed to protect individuals aged one and older from tick-borne encephalitis (TBE). This vaccine offers benefits to travelers and individuals residing in areas where TBE is prevalent, including military personnel. TICOVAC is developed using a master virus that closely resembles the natural TBE virus, allowing it to generate antibodies capable of neutralizing the natural TBE virus.

In November 2022, Substipharm, a French pharmaceutical company, acquired the IMOJEV Japanese encephalitis vaccine from Sanofi S.A. for an undisclosed amount. This acquisition enhances Substipharm's position in the encephalitis treatment market and complements its geographic expansion efforts. Sanofi S.A. is a French pharmaceutical company known for manufacturing a wide range of medicines and vaccines, including the encephalitis vaccine.

Major players in the encephalitis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Vir Biotechnology, Torrent Pharmaceuticals Ltd., Valneva SE, Sangamo Therapeutics, Xenon Pharmaceuticals, Tiziana Life Sciences, Vivet Therapeutics, Tetraphase Pharmaceuticals, QED Therapeutics.

North America was the largest region in the encephalitis treatment market in 2023. The regions covered in encephalitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the encephalitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Encephalitis can be categorized into two main types are primary encephalitis and secondary encephalitis. Primary encephalitis involves inflammation originating directly within the brain, rather than being a result of an infection originating elsewhere in the body. Treatment for primary encephalitis includes the use of antiviral medications, supportive care, and symptom management. The various treatment approaches are employed, encompassing antiviral agents, steroid injections, antibiotics, immunoglobulin therapy, plasmapheresis, and other treatments. These treatments can be administered via different routes, including oral, parenteral, and other methods. Diagnosing encephalitis involves employing various types of tests such as imaging tests, blood tests, biopsies, and other diagnostic procedures. These diagnostic tests are conducted by healthcare facilities like hospitals, specialty clinics, and others.

This report provides encephalitis treatment market statistics, including encephalitis treatment industry global market size, regional shares, competitors with an encephalitis treatment market share, detailed encephalitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the encephalitis treatment industry. This encephalitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The encephalitis treatment market consists of revenues earned by entities by providing plasmapheresis, immunoglobulin therapy, computed tomography (CT scans), magnetic resonance imaging (MRI) and magnetoencephalography (MEG) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalitis treatment market also includes sales of immunosuppressant drugs, antiseizure medicines and immunomodulators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.